AR and neoplasm: Initially, the studies revealed that testosterone impairs docetaxel antitumor activity through two different mechanisms: first, by impairing docetaxel tumor accumulation, thereby reducing tubulin stabilization; and second, by activating the AR pathway, thereby interfering with docetaxel‐induced cell death.